Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer.

While the present study showed a trend toward higher in-patient costs for de Gramont (other than to receive chemotherapy) these differences did not reach statistical significance (de Gramont vs Lokich, mean difference=£874, P =0.181, de Gramont vs raltitrexed, mean difference=£828, P =0.206), although this must be considered in the light of the small sample size.

also in 53,322 other papers